85 related articles for article (PubMed ID: 34048461)
1. Cutaneous leishmaniasis (Leishmania major infection) in Dutch troops deployed in northern Afghanistan: epidemiology, clinical aspects, and treatment.
van Thiel PP; Leenstra T; de Vries HJ; van der Sluis A; van Gool T; Krull AC; van Vugt M; de Vries PJ; Zeegelaar JE; Bart A; van der Meide WF; Schallig HD; Faber WR; Kager PA
Am J Trop Med Hyg; 2010 Dec; 83(6):1295-300. PubMed ID: 21118937
[TBL] [Abstract][Full Text] [Related]
2. Unmasking the Mechanism behind Miltefosine: Revealing the Disruption of Intracellular Ca
Benaim G; Paniz-Mondolfi A
Biomolecules; 2024 Mar; 14(4):. PubMed ID: 38672424
[TBL] [Abstract][Full Text] [Related]
3. [Successful Treatment of Therapy-refractory Acanthamoeba Keratitis with Systemic Miltefosine and Topical Voriconazole].
Schwarzer P; Blaser F; Sellner M; Rauthe SC; Tandogan T; Tappeiner C; Goldblum D
Klin Monbl Augenheilkd; 2024 Apr; 241(4):406-408. PubMed ID: 38653269
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of a single dose pentamidine (7mg/kg) for patients with cutaneous leishmaniasis caused by L. guyanensis: a pilot study.
Gadelha EP; Talhari S; Guerra JA; Neves LO; Talhari C; Gontijo B; Silva Junior RM; Talhari AC
An Bras Dermatol; 2015; 90(6):807-13. PubMed ID: 26734860
[TBL] [Abstract][Full Text] [Related]
5. Activity of the Di-Substituted Urea-Derived Compound I-17 in
Dos Santos JV; Medina JM; Dias Teixeira KL; Agostinho DMJ; Chorev M; Diotallevi A; Galluzzi L; Aktas BH; Gazos Lopes U
Pathogens; 2024 Jan; 13(2):. PubMed ID: 38392842
[TBL] [Abstract][Full Text] [Related]
6. Synthetic biology for combating leishmaniasis.
Khandibharad S; Singh S
Front Microbiol; 2024; 15():1338749. PubMed ID: 38362504
[TBL] [Abstract][Full Text] [Related]
7. First report of cutaneous leishmaniasis caused by Leishmania donovani in Ethiopia.
Amare GA; Mekonnen GG; Kassa M; Addisu A; Kendie DA; Tegegne B; Abera A; Tadesse D; Getahun S; Wondmagegn YM; Merdekios B; Asres MS; van Griensven J; Van der Auwera G; van Henten S; Pareyn M
Parasit Vectors; 2023 Dec; 16(1):457. PubMed ID: 38104111
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes of cutaneous leishmaniasis due to Leishmania aethiopica: A systematic review and meta-analysis.
Alemu AY; Derseh L; Kaba M; Gadisa E; Alemu K
PLoS One; 2023; 18(11):e0293529. PubMed ID: 37917604
[TBL] [Abstract][Full Text] [Related]
9. Community-based treatment of cutaneous leishmaniasis using cryotherapy and miltefosine in Southwest Ethiopia: the way forward?
van Henten S; Pareyn M; Tadesse D; Kassa M; Techane M; Kinfe E; Girma N; Demeke D; Mesay M; Kassa M; Temesgen R; Shewangizaw M; Massebo F; van Griensven J; Wegayehu T; Merdekios B
Front Med (Lausanne); 2023; 10():1196063. PubMed ID: 37886367
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Cutaneous Leishmaniasis with Sodium Stibogluconate and Allopurinol in a Routine Setting in Ethiopia: Clinical and Patient-Reported Outcomes and Operational Challenges.
van Henten S; Bialfew F; Hassen S; Tilahun F; van Griensven J; Abdela SG
Trop Med Infect Dis; 2023 Aug; 8(8):. PubMed ID: 37624352
[TBL] [Abstract][Full Text] [Related]
11. The story of dermatology in Gondar, Ethiopia and the promise of global health.
Revankar RR; Sinknew A; Bilcha K; Woldetensay M; Stoff BK
JAAD Int; 2023 Sep; 12():149-150. PubMed ID: 37409318
[No Abstract] [Full Text] [Related]
12. The leishmaniases in Kenya: A scoping review.
Grifferty G; Shirley H; O'Brien K; Hirsch JL; Orriols AM; Amechi KL; Lo J; Chanda N; El Hamzaoui S; Kahn J; Yap SV; Watson KE; Curran C; Atef AbdelAlim A; Bose N; Cilfone AL; Wamai R
PLoS Negl Trop Dis; 2023 Jun; 17(6):e0011358. PubMed ID: 37262045
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous leishmaniasis due to
Mengeot L; Yombi JC; Baeck M
JAAD Case Rep; 2022 Feb; 20():72-75. PubMed ID: 35128017
[No Abstract] [Full Text] [Related]
14. Miltefosine for the treatment of cutaneous leishmaniasis-A pilot study from Ethiopia.
van Henten S; Tesfaye AB; Abdela SG; Tilahun F; Fikre H; Buyze J; Kassa M; Cnops L; Pareyn M; Mohammed R; Vogt F; Diro E; van Griensven J
PLoS Negl Trop Dis; 2021 May; 15(5):e0009460. PubMed ID: 34048461
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of intralesional sodium stibogluconate for the treatment of localized cutaneous leishmaniasis at Boru Meda general hospital, Amhara, Ethiopia: Pragmatic trial.
Tilahun Zewdu F; Tessema AM; Zerga AA; van Henten S; Lambert SM
PLoS Negl Trop Dis; 2022 Sep; 16(9):e0010578. PubMed ID: 36084153
[TBL] [Abstract][Full Text] [Related]
16. Miltefosine for new world cutaneous leishmaniasis.
Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
[TBL] [Abstract][Full Text] [Related]
17. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.
Machado PR; Ampuero J; Guimarães LH; Villasboas L; Rocha AT; Schriefer A; Sousa RS; Talhari A; Penna G; Carvalho EM
PLoS Negl Trop Dis; 2010 Dec; 4(12):e912. PubMed ID: 21200420
[TBL] [Abstract][Full Text] [Related]
18. Treatment of New World cutaneous leishmaniasis with miltefosine.
Soto J; Berman J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S34-40. PubMed ID: 16930649
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
